- for speed listening, go to the settings wheel on the bottom right of the video and choose playback speed - after one minute video becomes high-resolution
Elior has posted strong full-year results, and Free Cash flow generation was above our expectations at >€200m. However, this was boosted by a
EBITDA margins are improving faster than we expected, driving operating cash flow
The new shares issued by Elior represent <0.3% of the equity. Although it will be a relief to the company that it can
A share buyback of up to €252m over the next 18 months is an eye-catching headline, but we expect the actual buyback outlay will be much smaller and back-ended. The buyback authorisation figure is sized on 10% of outstanding shares at €10 per share, bu
Please find our updated analysis here.
Elior surprised us with the pace of margin recovery in H223 and we do not expect that performance to reverse in FY24. The acquisition of
Elior's top line was well above our expectations driving a higher EBITDA. We had estimated that price rises to recover inflation would be delayed into 2024, bu
Elior continues to rely on its banks for liquidity as it tries to rebuild margins. Anything that pushes away pricing concerns is to be welcomed. The
Although the price paid has not been made public, the US acquisition is small. The business provides meals to 14,000 private school pupils in
Boris Derichebourg was already the COO of Elior France, so his appointment as the Chair and CEO of the French business is not surprising. Our modelling shows
Please find our updated analysis here.
Elior is relying on the banks to provide liquidity as it works to restore profitability. After a good start to the year against Omnicron-impacted comps, H2 has seen improvement taper off.
The Q3 headline numbers are overshadowed by the continuing difficulty of improving margins in an inflationary environment. EBIT margins for
Elior is making progress on cost recovery, but the process isn’t quick. Our concern about Elior is the ability to achieve inflationary price rises. H1 was
Elior shareholders have approved the stock-funded acquisition of DMS. This vote
The European Commission has approved the DMS transaction. This was largely expected. The main outstanding hurdle is
Ahead of the Elior shareholder vote on April 18th to approve the DMS acquisition, Elior this morning published the meeting agenda/resolutions, along with
Quantum and timing of Elior's EBITDA recovery remain highly uncertain. And while the pending DMS contribution will be moderately deleveraging, we still see value cushion under